Table 3.
Treatment in Pre-COVID and In-COVID Periods
| Type of Injections | Bevacizumab (Avastin) | Aflibercept (Eylea) | Ranibizumab (Lucentis) | Total |
|---|---|---|---|---|
| Pre-COVID (Total Patients = 607) | ||||
| Number of injections | 475 (67.4%) | 168 (23.8%) | 62 (8.8%) | 705 |
| In-COVID (Total Patients = 394) | ||||
| Number of injections | 313 (59.8%) | 160 (30.6%) | 50 (9.6%) | 523 |
| Number of injections in Pre-COVID versus In-COVID | P-value>0.9 | |||